(MedPage Today) — MONTREAL — Diabetic retinopathy severity and the risk of vision-threatening complications decreased significantly in patients treated with the investigational VEGF inhibitor tarcocimab, a randomized, sham-controlled study…
Source: MedPage Today — Headlines
